Physician profile
Kevin S Campbell
NPI 1497833834
$4,790.99
in general payments reported to CMS, 2019-2025
32 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $781 · 2021: $1,092 · 2022: $885 · 2023: $774 · 2024: $817 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,764.51 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,349.43 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Glaxosmithkline, LLC. | $1,272.10 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $534.94 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $275.04 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $161.66 | 2019-2023 | Camzyos |
| Lilly USA, LLC | $146.98 | 2020-2024 | Mounjaro, Jardiance |
| Allergan, INC. | $143.19 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $108.29 | 2021 | |
| Novo Nordisk INC | $96.20 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $78.52 | 2020-2021 | |
| Esperion Therapeutics, INC. | $70.31 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.51 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $52.73 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $39.35 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.69 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.91 | 2023 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $31.92 | 2020 | |
| Amarin Pharma, INC. | $31.62 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.23 | 2021-2022 | |
| Eisai INC. | $26.67 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.19 | 2021-2022 | |
| Lundbeck LLC | $24.63 | 2024 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $23.68 | 2020 | |
| Dexcom, INC. | $23.19 | 2023 | Dexcom G6 Transmitter |
| Cranial Technologies, INC | $20.15 | 2025 | Doc Band |
| Philips North America LLC | $19.11 | 2024 | (Ck7) Extended Holter |
| Medtronic, INC. | $18.63 | 2023 | Endurant Iis |
| Nestle Healthcare Nutrition INC. | $15.69 | 2021 | |
| Boston Scientific Corporation | $13.22 | 2024 | |
| Aytu Biopharma, INC. | $12.56 | 2019 | |
| Sumitomo Pharma America, INC. | $8.65 | 2023 | Gemtesa |
| Bardy Diagnostics, INC. | $8.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.